EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase II)Multizentrische StudieOpen Access · CC BY 4.0

Patient‐Reported Outcomes After Treatment With OnabotulinumtoxinA for Platysma Prominence: Results From a Phase 2 Dose‐Ranging Study

Shannon Humphrey iD, Sandhya Shimoga, Joely Kaufman, David Bank, Brian Biesman, Christy Harutunian, Grace S West, Warren Tong, Vaishali Patel

Journal of Cosmetic Dermatology · 2026-04 · 25 (4)

DOI: 10.1111/jocd.70821 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of Cosmetic Dermatology, online erschienen am 03.04.2026. Verfasst von Shannon Humphrey und 8 weiteren Autor:innen. Beteiligte Einrichtung: Humphrey Cosmetic Dermatology, Vancouver, British Columbia, Canada. Hauptthemen laut MEDLINE: Botulinum Toxins, Type A, Patient Reported Outcome Measures, Skin Aging, Cosmetic Techniques. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Allergan Aesthetics, an AbbVie company.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Repetitive contractions of the platysma muscle may result in vertical neck bands that blunt the jawline (i.e., platysma prominence [ PP ]). We report patient‐reported outcomes ( PROs ) from a phase 2 study evaluating onabotulinumtoxinA ( onabotA ) for moderate or severe PP.

Methods

Subjects were randomized 1:1:1 to onabotA dose 1 (26 U, 31 U, or 36 U), onabotA dose 2 (52 U, 62 U, or 72 U), or placebo. De novo, validated, fit‐for‐purpose PROs were used to assess treatment satisfaction, bother with vertical neck bands and jawline, jawline definition, and psychosocial impact.

Results

Subjects with PRO data ( N = 164; mean age, 50.0 years) were predominantly female (95.1%) and White (93.9%). Response rates for improvement in both onabotA dose groups were higher than placebo for treatment satisfaction, bother with vertical neck bands and jawline, as well as jawline definition (unadjusted p < 0.05 for all). Greater improvements in treatment satisfaction and psychosocial impact were observed in both dose groups versus placebo based on the mean total scores on the Appearance of Neck and Lower Face Questionnaire (ANLFQ): Satisfaction and the mean change from baseline in ANLFQ: Impacts total score, respectively (unadjusted p < 0.0001 for all). Response rates generally peaked across all measures at day 14 or 30 for both dose groups, with a trend in improvement continuing through day 120.

Conclusions

Compared with placebo, both onabotA dose groups reported greater satisfaction with the effect of treatment, improvements in jawline definition and psychological impact, as well as reductions in bother due to vertical neck bands and jawline. Trial Registration ClinicalTrials.gov: NCT03915067

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Botulinum Toxins, Type APatient Reported Outcome MeasuresSkin AgingCosmetic TechniquesSuperficial Musculoaponeurotic SystemNeuromuscular AgentsHumansFemaleMiddle AgedPatient SatisfactionAdultMaleTreatment OutcomeDose-Response Relationship, DrugDouble-Blind Method

Stichwörter der Autor:innen

botulinum toxin Acosmetic techniquesneckpatient satisfactionskin agingtreatment outcome

Substanzen

Botulinum Toxins, Type Aonabotulinum toxin ANeuromuscular Agents

Autor:innen und Institutionen

  • Humphrey Cosmetic Dermatology, Vancouver, British Columbia, Canada.
  • AbbVie, Irvine, California, USA.
  • Skin Associates of South Florida, Coral Gables, Florida, USA.
  • The Center for Dermatology, Cosmetic & Laser Surgery, Mount Kisco, New York, USA.
  • Private Practice, Nashville, Tennessee, USA.
  • Allergan Aesthetics, an AbbVie company, Irvine, California, USA.

ORCID-Profile: Shannon Humphrey

Förderung

  • Allergan Aesthetics, an AbbVie company

Zitieren

APA

Humphrey, S., Shimoga, S., Kaufman, J., Bank, D., Biesman, B., Harutunian, C., West, G. S., Tong, W., & Patel, V. (2026). Patient‐Reported Outcomes After Treatment With OnabotulinumtoxinA for Platysma Prominence: Results From a Phase 2 Dose‐Ranging Study. Journal of Cosmetic Dermatology, 25(4). https://doi.org/10.1111/jocd.70821

Vancouver

Humphrey S, Shimoga S, Kaufman J, Bank D, Biesman B, Harutunian C, et al. Patient‐Reported Outcomes After Treatment With OnabotulinumtoxinA for Platysma Prominence: Results From a Phase 2 Dose‐Ranging Study. Journal of Cosmetic Dermatology. 2026;25(4). doi:10.1111/jocd.70821

BibTeX
@article{Humphrey2026,
  author = {Humphrey, Shannon and Shimoga, Sandhya and Kaufman, Joely and Bank, David and Biesman, Brian and Harutunian, Christy and West, Grace S and Tong, Warren and Patel, Vaishali},
  title = {Patient‐Reported Outcomes After Treatment With OnabotulinumtoxinA for Platysma Prominence: Results From a Phase 2 Dose‐Ranging Study},
  journal = {Journal of Cosmetic Dermatology},
  year = {2026},
  volume = {25},
  number = {4},
  doi = {10.1111/jocd.70821}
}
Kostenlos starten →